Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology (CRDF) reported a Q3 loss of $8.9M, or 12 cents per share, beating analyst expectations of a 14 cents per share loss. Revenue was $171,000, exceeding forecasts of $113,000. The company is based in San Diego and operates in the molecular diagnostics sector.

Original reporting
Published Nov 12, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cardiff Oncology: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$CRDFBearishMed
01

Why it matters

The earnings release provides the first public numbers for the quarter, offering new data for traders.

02

Market read

Micro‑cap earnings with modest beat on loss but still a loss; likely limited price movement but may attract short‑term traders.

03

What to watch

The company’s cash position and upcoming clinical milestones are not disclosed but could materially affect future valuation.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Cardiff Oncology is a molecular diagnostic company focused on oncology testing. The Q3 results were generated by Automated Insights from Zacks data.

Company-level read

Ticker impact

$CRDFBearishMedium confidence
Context

Cardiff Oncology reported Q3 loss of $8.9M, 12c EPS loss beating estimates of 14c, revenue $171k beating $113k forecasts.

Expected impact

likely slight downside as market prices in loss despite beat on loss per share.

Evidence & confidence

Micro‑cap earnings with modest beat on loss but still a loss; investors may trim positions.

Market effects

Limited impact on broader biotech sector; reflects ongoing challenges for early‑stage diagnostics firms.

Primarily U.S. micro‑cap investors; no broader regional effect.

Low global relevance.

Counterpoint

Despite the loss, the beat on loss per share could signal improving cost control, suggesting a potential rebound if cash runway extends.

Key entities

  • Cardiff Oncology, Inc.

    Micro‑cap biotech reporting Q3 earnings.

Related articles

$CRDFHighAI 9/10

Why is Cardiff Oncology stock surging today?

Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.

$CRDFMed

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms All patients remaining in t

$CRDFMedAI 8/10

FDA grants orphan drug status to Cardiff’s onvansertib for CMML

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

$CRDFMed

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m